231 related articles for article (PubMed ID: 24363283)
21. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Chllamma MK; Cook N; Dhani NC; Giby K; Dodd A; Wang L; Hedley DW; Moore MJ; Knox JJ
Br J Cancer; 2016 Sep; 115(6):649-54. PubMed ID: 27467054
[TBL] [Abstract][Full Text] [Related]
22. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.
Correale P; Montagnani F; Miano S; Sciandivasci A; Pascucci A; Petrioli R; Testi W; Tanzini G; Francini G
J Chemother; 2008 Feb; 20(1):119-25. PubMed ID: 18343754
[TBL] [Abstract][Full Text] [Related]
23. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
[TBL] [Abstract][Full Text] [Related]
24. Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma: Case Report.
Yang B; He JP; Yuan ML; Li W; Jiao H; You X; Liu XR; Zhao J; Li CL; Fu XB; Liao ZY; Yi C
Medicine (Baltimore); 2017 Sep; 96(37):e8018. PubMed ID: 28906385
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
El-Hadaad HA; Wahba HA
J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Herman JM; Wild AT; Wang H; Tran PT; Chang KJ; Taylor GE; Donehower RC; Pawlik TM; Ziegler MA; Cai H; Savage DT; Canto MI; Klapman J; Reid T; Shah RJ; Hoffe SE; Rosemurgy A; Wolfgang CL; Laheru DA
J Clin Oncol; 2013 Mar; 31(7):886-94. PubMed ID: 23341531
[TBL] [Abstract][Full Text] [Related]
27. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Gill S; Ko YJ; Cripps C; Beaudoin A; Dhesy-Thind S; Zulfiqar M; Zalewski P; Do T; Cano P; Lam WYH; Dowden S; Grassin H; Stewart J; Moore M
J Clin Oncol; 2016 Nov; 34(32):3914-3920. PubMed ID: 27621395
[TBL] [Abstract][Full Text] [Related]
28. Viscum album L. Therapy in Oncology: An Update on Current Evidence.
Thronicke A; Schad F; Debus M; Grabowski J; Soldner G
Complement Med Res; 2022; 29(4):362-368. PubMed ID: 35325897
[TBL] [Abstract][Full Text] [Related]
29. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
[TBL] [Abstract][Full Text] [Related]
30. Disappearance of an advanced adenomatous colon polyp after intratumoural injection with Viscum album (European mistletoe) extract: a case report.
von Schoen-Angerer T; Goyert A; Vagedes J; Kiene H; Merckens H; Kienle GS
J Gastrointestin Liver Dis; 2014 Dec; 23(4):449-52. PubMed ID: 25532007
[TBL] [Abstract][Full Text] [Related]
31. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
32. Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Diaz Beveridge R; Alcolea V; Aparicio J; Segura Á; García J; Corbellas M; Fonfría M; Giménez A; Montalar J
JOP; 2014 Jan; 15(1):19-24. PubMed ID: 24413779
[TBL] [Abstract][Full Text] [Related]
33. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
35. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Oettle H; Riess H; Stieler JM; Heil G; Schwaner I; Seraphin J; Görner M; Mölle M; Greten TF; Lakner V; Bischoff S; Sinn M; Dörken B; Pelzer U
J Clin Oncol; 2014 Aug; 32(23):2423-9. PubMed ID: 24982456
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
37. Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with
Werthmann PG; Kempenich R; Lang-Avérous G; Kienle GS
World J Gastroenterol; 2019 Mar; 25(12):1524-1530. PubMed ID: 30948915
[TBL] [Abstract][Full Text] [Related]
38. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
Schad F; Axtner J; Kröz M; Matthes H; Steele ML
Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
40. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
